Default: Vaccine

ISSN: 0264-410X

Journal Home

Journal Guideline

Vaccine Q1 Unclaimed

Elsevier BV Netherlands
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 175. It has a price of 2395 €. It has an SJR impact factor of 1,683 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -




SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Best articles

A look at new models to support vaccine research and development

View more

A model to estimate the potential economic benefits of measles eradication for the United States

View more

A possible explanation for the discrepancy between ELISA and neutralising antibodies to tetanus toxin

View more

Alkyl-polyacrylate esters are strong mucosal adjuvants

View more

An editorial policy statement

View more

Analysis of factors influencing vaccine uptake from various perspectives

View more

Analysis of factors influencing vaccine uptake: perspective from Spain

View more

Analysis of factors influencing vaccine uptake: perspectives from Belgium

View more

Analysis of recombinant mouse zona pellucida protein 2 (ZP2) constructs for immunocontraception

View more

Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines

View more

Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases

View more

Antigen receptors and dendritic cells

View more

Benefit and risk of vaccination as seen by the general public and the media

View more

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose

View more

Business perspectives of a European vaccine manufacturer

View more

CHILD Profile: an immunization registry and more--a new approach to tracking and surveillance

View more

Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal

View more

Cost-effectiveness of hepatitis A and B vaccination programme in Germany

View more

Detection of adverse events: what are the current sensitivity limits during clinical development?

View more

Developing vaccines involving new technologies to ensure safety and timely licensure

View more

Development of a transgenic mouse neurovirulence test for oral poliovirus vaccine: international collaborative study 1993-1999

View more

DNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development

View more

Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA®

View more

Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply

View more


No comments ... Be the first to comment!